PGT-FAST

PGT-FAST is a rapid preimplantation genetic testing assay performed prior to embryo transfer during in vitro fertilization (IVF).

The test analyzes biopsied embryonic cells to evaluate chromosomal status and assess all 24 chromosomes (22 autosomes plus X and Y chromosomes).

Detectable Chromosomal Abnormalities

• Numerical Chromosomal Abnormalities

Aneuploidies involving whole chromosome gains or losses

• Structural Chromosomal Abnormalities

Large chromosomal deletions and duplications ≥5 Mb

Clinical Purpose

To facilitate the selection of euploid embryos for transfer and improve reproductive outcomes.

• Ultra-rapid turnaround time (~15 hours)
• Comprehensive chromosome screening
• High analytical accuracy using NGS technology
• Supports timely clinical decision-making during IVF treatment
• Optimizes embryo selection strategies in assisted reproductive technology (ART) programs

• Trophectoderm biopsy of blastocyst-stage embryos
• NGS-based chromosomal analysis
• Sequencing performed on the Illumina platform
• Advanced bioinformatics analysis
• High sensitivity and specificity for detecting chromosomal abnormalities

Chromosomal abnormalities are a major cause of:

• Implantation failure
• Early miscarriage
• Chromosomal disorders and genetic syndromes in offspring

Preimplantation genetic testing can:

• Improve selection of chromosomally normal (euploid) embryos
• Increase the likelihood of successful implantation and pregnancy
• Clinical Applications
• Detection of embryonic chromosomal abnormalities prior to embryo transfer
• Support for embryo selection during IVF treatment
• Integration into routine assisted reproductive technology (ART) workflows

• Couples undergoing IVF treatment
• Patients seeking enhanced selection of euploid embryos
• Couples aiming to optimize pregnancy outcomes and reduce the risk of chromosomal abnormalities in offspring

• IVF embryo generation
• Embryo biopsy
• NGS-based genetic analysis
• Bioinformatics data interpretation
• Result reporting within 15 hours
• Selection of the most appropriate embryo for transfer

• Significantly reduced turnaround time (15 hours)
• Improved identification of euploid embryos
• Potential improvement in implantation and clinical pregnancy rates
• Reduced risk of miscarriage associated with embryonic aneuploidy
• Faster clinical decision-making
• Reduced emotional burden during IVF treatment